ORAL VERAPAMIL EFFECTS ON GLOBAL AND REGIONAL LEFT VENTRICULAR DIASTOLIC FILLING IN HYPERTROPHIC CARDIOMYOPATHY
スポンサーリンク
概要
- 論文の詳細を見る
To assess the effects of oral verapamil therapy on global and regional left ventricular (LV) diastolic filling of hypertrophic cardiomyopathy (HCM), we studied 9 patients with HCM by radionuclide ventriculography and M-mode echocardiography before and after 2 weeks of oral verapamil therapy (240 mg/day). LV regional function was assessed by subdividing the LV region of interest into 4 regions from which global, septal, apical and lateral time-activity curves and their first-derivative curves were derived. Diastolic asynchrony during early diastole was measured as the sum of the absolute values (total Δt) of the time differences ( Δt) from peak filling rate in the global left ventricle to that in each of the 3 regions. Verapamil did not alter LV systolic function globally and regionally. Global LV peak filling rate improved after verapamil therapy from 1.92±0.59 to 2.35±0.63 end-diastolic counts/s (p<0.02) without altering regional peak filling rates significantly. Global and regional times to peak filling rate showed a shortening or no change despite a tendency to increase in the diastolic time after verapamil therapy. The total Δt decreased from 93±61 to 41±23 ms after verapamil (p<0.05), indicating more synchronous LV diastolic filling after verapamil. There was a negative correlation between the global peak filling rate and the total Δt (r= -0.54, p<0.05, n=18), suggesting that the global peak filling rate may improve after verapamil therapy in association with the decrease in the asynchronous LV diastolic filling. Thus, verapamil was effective in improving impaired LV filling in HCM, which might be related to reduction in regional LV diastolic asynchronous filling.
- 社団法人日本循環器学会の論文
- 1990-11-20
著者
-
Yamamoto Takeshi
Department Of Medicine And Clinical Science Division Of Cardiology Yamaguchi University Graduate Sch
-
KUSUKAWA REIZO
Japanese Circulation Society(JCS)Task Force Committee on Chronic Myocarditis
-
Kusukawa Reizo
Department Of Cardiology Tenri Hospital
-
Kusukawa Reizo
The Department Of Cardiology Tenri Hospital
-
Kusukawa R.
Yamaguchi University School Of Medicine
-
OZAKI MASAHARU
Second Department of Internal Medicine, Yamaguchi University
-
YAMAGISHI TAKASHI
Second Department of Internal Medicine, Yamaguchi University
-
Obayashi Masakazu
Division Of Cardiovascular Medicine Department Of Medical Bioregulation Yamaguchi Univesity Graduate
-
Ozaki Masaharu
2nd. Dept. Of Internal Med. Yamaguchi Univ. Ube Yamaguchi Japan
-
KUSUKAWA REIZO
Second Department of Medicine, Yamaguchi University School of Medicine
-
Kusukawa R
Department Of Cardiology Tenri Hospital
-
Kusukawa R
The 2nd Departmen Of Internal Medicine Yamaguchi University School Of Medicine
-
Kusukawa Reizo
The Second Department Of Internal Medicine Yamaguchi University School Of Medicine
-
Kusukawa Reizo
Second Department Of Internal Medicine Yamaguchi University School Of Medicine:national Hamada Hospi
-
Kusukawa Reizo
Department Of Cardiology Tenri Hospilal
-
Kusukawa Reizo
Departmet Of Cardiology Tenri Hospital
-
Ozaki Masaharu
Second Department Of Internal Medicine Yamaguchi University
-
Yamamoto Takeshi
Division Of Cardiovascular Medicine Department Of Medical Bioregulation Yamaguchi University School
-
Ozakl Masaharu
Department Of Internal Medicine Yamaguchi University School Of Medicine
-
Kusukawa Reizo
Tenri Hosp. Div. Of Cardiol. Tenri. Nara Prfe
-
Kusukawa Reizo
Central Lab. Kyoto Univ. Hosp.
-
Obayashi Masakazu
Department Of Medical Bioregulation Division Of Cardiovascular Medicine Yamaguchi University School
-
Obayashi Masakazu
Department Of Medical Bioregulation Division Of Cardiovascular Medicine Yamaguchi University School
-
Yamamoto Takeshi
Division Of Cardiology Tokuyama Central Hospital
関連論文
- Guideline for Diagnosing Chronic Myocarditis
- PJ-573 Dantrolene Prevents Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) by Correcting Abnormal Ca^ Release through the Ryanodine Receptor(PJ096,Arrhythmia, Others (Clinical/Pathophysiology) 4 (A),Poster Session (Japanese),The 73rd Annu
- PJ-068 Abnormally Tight Domain-Domain Interaction at Mutation Site could be a Primary Cause of Catecholaminergic Polymorphic Ventricular Tachycardia(PJ012,Calcium Handling, Cardiac Function (Basic) (M),Poster Session (Japanese),The 73rd Annual Scientific
- PJ-573 Dantrolene Prevents Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) by Correcting Abnormal Ca^ Release through the Ryanodine Receptor(PJ096,Arrhythmia, Others (Clinical/Pathophysiology) 4 (A),Poster Session (Japanese),The 73rd Annu
- PJ-068 Abnormally Tight Domain-Domain Interaction at Mutation Site could be a Primary Cause of Catecholaminergic Polymorphic Ventricular Tachycardia(PJ012,Calcium Handling, Cardiac Function (Basic) (M),Poster Session (Japanese),The 73rd Annual Scientific
- 5 Decreased affinity of calmodulin binding to RyR2 may cause leaky channel in CPVT-associated mutation(Young Investigator's Award for International Students Finalists Lecture (YIA International),The 73rd Annual Scientific Meeting of The Japanese Circulati
- 3 Correction of RyR2 Defects as a New Therapeutic Strategy against Heart Failure(Novel Therapeutic Strategies against Heart Failure,KSC-JCS Joint Symposium (KSC-JCS Joint Symposium) (I),The 73rd Annual Scientific Meeting of The Japanese Circulation Societ
- Role of ryanodine receptor as a Ca^ regulatory center in normal and failing hearts
- Defective Ca^ Cycling as a Key Pathogenic Mechanism of Heart Failure(Molecular Mechanisms)
- PJ-203 Dantrolene, a therapeutic agent for malignant hyperthermia, inhibits catecholaminergic polymorphic ventricular tachycardia : Insights from a RyR2 R2474S/+ knock-in mouse model(Arrhythmia, basic(05)(A),Poster Session(Japanese),The 72nd Annual Scient